Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
AEON Biopharma, Inc. (AEON) is a clinical-stage biopharmaceutical company focused on the development and commercialization of botulinum toxin type A therapeutics for neurological and aesthetic indications. The company operates within the biopharmaceutical and specialty therapeutics industries, targeting conditions with significant unmet medical need where neuromodulator-based treatments are clinically established. AEON does not currently generate commercial revenue and remains dependent on clinical development progress and external financing.
AEON’s primary product candidate is ABP‑450, an investigational botulinum toxin type A complex being evaluated for therapeutic indications such as cervical dystonia and chronic migraine, with potential future applications in medical aesthetics. The company’s strategy centers on differentiated dosing, duration of effect, and regulatory positioning in established toxin markets. AEON was founded in the early 2010s and became publicly traded in 2023 following a business combination with Priveterra Acquisition Corp., transitioning from a private development-stage entity to a Nasdaq-listed company.
Business Operations
AEON’s operations are organized around a single reportable operating segment: biopharmaceutical research and development, with substantially all resources allocated to advancing ABP‑450 through clinical trials, regulatory engagement, and manufacturing readiness. The company’s activities include clinical trial management, regulatory strategy, intellectual property development, and preparation for potential commercialization. As of the most recent public disclosures, AEON has no approved products and no product sales.
The company relies on third-party partners for manufacturing, clinical trial execution, and certain development functions, rather than maintaining in-house manufacturing infrastructure. AEON holds licensing rights to the botulinum toxin asset underlying ABP‑450 and collaborates with external contract development and manufacturing organizations. Domestic operations are primarily administrative and clinical oversight–focused, with international exposure tied to manufacturing and development partnerships.
Strategic Position & Investments
AEON’s strategic direction emphasizes advancing ABP‑450 through late-stage clinical development in large, well-established toxin markets where existing products generate multibillion-dollar global revenues. The company seeks to position its candidate as a differentiated alternative based on clinical profile, dosing characteristics, and potential cost or access advantages, subject to regulatory outcomes.
The company has not disclosed a broad portfolio of acquisitions or diversified investments, instead maintaining a concentrated, single‑asset strategy. AEON’s most significant strategic transaction to date is its merger with Priveterra Acquisition Corp., which provided public-market access and development capital. Public disclosures do not indicate ownership of additional commercial-stage subsidiaries or a diversified pipeline beyond ABP‑450. Data inconclusive based on available public sources regarding expansion into non-toxin technologies.
Geographic Footprint
AEON is headquartered in Irvine, California, and its corporate presence is primarily concentrated in the United States. Clinical development activities are conducted in U.S.-based trial sites, with regulatory engagement focused on the U.S. Food and Drug Administration.
International exposure is indirect and primarily related to manufacturing and licensing relationships with overseas partners, including ties to Asia, where the underlying botulinum toxin technology originated. AEON does not currently report material commercial operations or regional offices outside North America, though future commercialization could expand its footprint into Europe and Asia‑Pacific, subject to regulatory approvals.
Leadership & Governance
AEON is led by an executive team with experience in biopharmaceutical development, capital markets, and neurology-focused therapeutics. The company’s governance structure reflects its status as a development-stage public issuer, with emphasis on clinical execution, regulatory strategy, and capital stewardship.
Key executives include:
- Marc Forth – Chief Executive Officer
- Matthew J. Fagan – Chief Financial Officer
- Stephen Barker – Chief Development Officer
The leadership team emphasizes disciplined clinical development, strategic capital allocation, and leveraging established toxin market dynamics to support long-term value creation. Certain executive biographies and tenure details vary across disclosures; where inconsistencies exist, data inconclusive based on available public sources.